Back to Search Start Over

Patient-related factors independently impact overall survival in patients with myelodysplastic syndromes: an MDS-CAN prospective study.

Authors :
Buckstein R
Wells RA
Zhu N
Leitch HA
Nevill TJ
Yee KW
Leber B
Sabloff M
St Hilaire E
Kumar R
Geddes M
Shamy A
Storring J
Kew A
Elemary M
Levitt M
Lenis M
Mamedov A
Zhang L
Rockwood K
Alibhai SM
Source :
British journal of haematology [Br J Haematol] 2016 Jul; Vol. 174 (1), pp. 88-101. Date of Electronic Publication: 2016 Mar 15.
Publication Year :
2016

Abstract

Unlabelled: Little is known about the effects of frailty, disability and physical functioning on the clinical outcomes for myelodysplastic syndromes (MDS). We investigated the predictive value of these factors on overall survival (OS) in 445 consecutive patients with MDS and chronic monomyelocytic leukaemia (CMML) enrolled in a multi-centre prospective national registry. Frailty, comorbidity, instrumental activities of daily living, disability, quality of life, fatigue and physical performance measures were evaluated at baseline and were added as covariates to conventional MDS-related factors as predictors of OS in Cox proportional hazards models. The median age was 73 years, and 79% had revised International Prognostic Scoring System (IPSS-R) risk scores of intermediate or lower. Frailty correlated only modestly with comorbidity. OS was significantly shorter for patients with higher frailty and comorbidity scores, any disability, impaired grip strength and timed chair stand tests. By multivariate analysis, the age-adjusted IPSS-R, frailty (Hazard ratio 2·7 (95% confidence interval [CI] 1·7-4·2), P < 0·0001) and Charlson comorbidity score (Hazard ratio 1·8 (95% CI 1·1-2·8), P = 0·01) were independently prognostic of OS. Incorporation of frailty and comorbidity scores improved risk stratification of the IPSS-R by 30% and 5%, respectively. These data demonstrate for the first time, the importance of considering frailty in prognostic models and a potential target for therapeutic intervention in optimizing clinical outcomes in older MDS patients.<br />Trial Registration: ClinicalTrials.gov Identifier: NCT02537990.<br /> (© 2016 John Wiley & Sons Ltd.)

Details

Language :
English
ISSN :
1365-2141
Volume :
174
Issue :
1
Database :
MEDLINE
Journal :
British journal of haematology
Publication Type :
Academic Journal
Accession number :
26991631
Full Text :
https://doi.org/10.1111/bjh.14033